Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourExpanding
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $4.96
Key levels
Resistance$3.62
Resistance$3.18
Support$2.80
Support$2.52
Latest news & SEC filings
AnalystB. Riley Securities repeats bullish call on Wave Life Sciences
AnalystB. Riley Securities keeps Buy rating on Wave Life Sciences, cuts target to $18
NewsWave Life Sciences Gives Development Update at 2026 Research Day
All WVE news →Wave Life Sciences is a biotech firm in the clinical testing phase that creates treatments aimed at ribonucleic acid. Its technology spans several approaches, such as silencing genes, editing RNA, and altering how genetic messages are spliced. The company is developing drug candidates for metabolic and liver conditions, a genetic lung and liver disorder, a muscle-wasting disease, and a neurodegenerative condition. It carries out its work in the United States and Singapore.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$11.00
SEPT Mid Target
$15.00
SEPT High Target
$29.00
Analyst Consensus
$15.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for WVE.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$12.52
25
Moat Score
NONE
3/9
Piotroski Score
0.2
Altman Z-Score
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 10,700 | - | Oct 5, 2026 |
| Verdine Gregory L. | director | Buy | 10,700 | - | Oct 5, 2026 |
| CORRIGAN MARK | director | Buy | 10,700 | - | Oct 5, 2026 |
| Rawcliffe Adrian | director | Buy | 10,700 | - | Oct 5, 2026 |
| HENRY CHRISTIAN O | director | Buy | 10,700 | - | Oct 5, 2026 |
| Tan Aik Na | director | Buy | 10,700 | - | Oct 5, 2026 |
| TAKANASHI KEN | director | Buy | 10,700 | - | Oct 5, 2026 |
| Wagner Heidi L | director | Buy | 10,700 | - | Oct 5, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-60.5%
3yr Revenue CAGR
127.1%
EPS Growth YoY
-72.86%
FCF Growth YoY
-23.9%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for WVE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $3.42 | 2,400 | $$8K | SELL |
| 21:00:08 | $3.42 | 11,846 | $$41K | SELL |
| 21:00:08 | $3.42 | 3,375 | $$12K | SELL |
| 21:00:07 | $3.42 | 20,228 | $$69K | SELL |
| 21:00:07 | $3.42 | 2,760 | $$9K | SELL |
5 dark pool trades shown · $$139K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for WVE, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $5 | Jan 15 | 65 | $$40 | 1 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Wave Life Sciences, Inc. (WVE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Wave Life Sciences, Inc. (WVE) is at $3.15, down 7.75% (-$0.27) at the Nov 12, 2026 close.
Latest WVE news — Nov 9, 2026: B. Riley Securities repeats bullish call on Wave Life Sciences · Nov 9, 2026: B. Riley Securities keeps Buy rating on Wave Life Sciences, cuts target to $18
The average analyst price target for WVE is $15.00, ranging from $11 to $29, based on 9 analysts. Latest: Oppenheimer maintains on Oct 28, 2026.
Analyst ratings for WVE: 0 Buy, 16 Hold, 2 Sell — consensus Hold.
WVE last reported on Oct 27, 2026: EPS -$0.30 vs -$0.33 expected — a beat of 8.8%.
WVE does not currently pay a dividend.
Support: $2.80, $2.52, $2.24. Resistance: $3.18, $3.62, $3.86.
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
Nov 9, 2026: B. Riley Securities repeats bullish call on Wave Life Sciences · Nov 9, 2026: B. Riley Securities keeps Buy rating on Wave Life Sciences, cuts target to $18 · Nov 5, 2026: Wave Life Sciences Gives Development Update at 2026 Research Day